Atrial Fibrillation Induced by Anticancer Drugs and Underling Mechanisms

Burashnikov, Alexander

doi:10.1097/fjc.0000000000001182

Cited by 7 publications

(4 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This oxidative stress can trigger structural and electrical remodeling of the atrial myocardium, which is a known substrate for AF development [ 41 ]. Moreover, anthracyclines can induce cellular apoptosis and disrupt cardiac calcium metabolism, further contributing to AF incidence [ 42 ]. In contrast, our findings differ from those of previous studies from the US [ 6 ] and Canada [ 11 ], where anthracycline use was not associated with increased AF risk, possibly because of different study population characteristics such as racial/ethnic differences [ 43 ].…”

Section: Discussionmentioning

confidence: 99%

Mid- and long-term risk of atrial fibrillation among breast cancer surgery survivors

Park,

Jung,

Yeo

et al. 2024

BMC Med

View full text Add to dashboard Cite

Background The risk of incident atrial fibrillation (AF) among breast cancer survivors, especially for younger women, and cancer treatment effects on the association remain unclear. This study aimed to investigate the risk of AF among breast cancer survivors and evaluate the association by age group, length of follow-up, and cancer treatment. Methods Using data from the Korean Health Insurance Service database (2010–2017), 113,232 women newly diagnosed with breast cancer (aged ≥ 18 years) without prior AF history who underwent breast cancer surgery were individually matched 1:5 by birth year to a sample female population without cancer (n = 566,160) (mean[SD] follow-up, 5.1[2.1] years). Sub-distribution hazard ratios (sHRs) and 95% confidence intervals (CIs) considering death as a competing risk were estimated, adjusting for sociodemographic factors and cardiovascular/non-cardiovascular comorbidities. Results BCS had a slightly increased AF risk compared to their cancer-free counterparts (sHR 1.06; 95% CI 1.00–1.13), but the association disappeared over time. Younger BCS (age < 40 years) had more than a 2-fold increase in AF risk (sHR 2.79; 95% CI 1.98–3.94), with the association remaining similar over 5 years of follow-up. The increased risk was not observed among older BCS, especially those aged > 65 years. Use of anthracyclines was associated with increased AF risk among BCS (sHR 1.57; 95% CI 1.28–1.92), which was more robust in younger BCS (sHR 1.94; 95% CI 1.40–2.69 in those aged ≤ 50 years). Conclusions Our findings suggest that younger BCS had an elevated risk of incident AF, regardless of the length of follow-up. Use of anthracyclines may be associated with increased mid-to-long-term AF risk among BCS. Graphical Abstract

show abstract

Section: Discussionmentioning

confidence: 99%

Mid- and long-term risk of atrial fibrillation among breast cancer surgery survivors

Park,

Jung,

Yeo

et al. 2024

BMC Med

View full text Add to dashboard Cite

show abstract

“…advanced age, obesity, diabetes and inflammation) may explain this association. In addition, cancer treatments, including surgery, radiation, chemotherapy, targeted therapies and high-dose corticosteroids, increase the risk of AF [153]. The most notable chemotherapeutics associated with AF are alkylating agents.…”

Section: (F ) Cancer and Related Therapymentioning

confidence: 99%

Advances in basic and translational research in atrial fibrillation

Barajas-Martínez

Zhang

et al. 2023

Phil. Trans. R. Soc. B

View full text Add to dashboard Cite

Atrial fibrillation (AF) is a very common cardiac arrhythmia with an estimated prevalence of 33.5 million patients globally. It is associated with an increased risk of death, stroke and peripheral embolism. Although genetic studies have identified a growing number of genes associated with AF, the definitive impact of these genetic findings is yet to be established. Several mechanisms, including electrical, structural and neural remodelling of atrial tissue, have been proposed to contribute to the development of AF. Despite over a century of exploration, the molecular and cellular mechanisms underlying AF have not been fully established. Current antiarrhythmic drugs are associated with a significant rate of adverse events and management of AF using ablation is not optimal, especially in cases of persistent AF. This review discusses recent advances in our understanding and management of AF, including new concepts of epidemiology, genetics and pathophysiological mechanisms. We review the current status of antiarrhythmic drug therapy for AF, new potential agents, as well as mechanism-based AF ablation. This article is part of the theme issue ‘The heartbeat: its molecular basis and physiological mechanisms’.

show abstract

“…Результаты ряда исследований и метаанализов показывают, что риск развития ФП наиболее высок в течение первых месяцев после постановки онкологического диагноза, т. е. тогда, когда интенсивность противоопухолевой терапии и сила проаритмогенных влияний наиболее высоки [10,12,[17][18][19][20]. В исследовании A. Guha и соавт.…”

Section: фибрилляция предсердий и злокачественные новообразованияunclassified

Atrial fibrillation and malignant neoplasms: state of the problem

Kostin,

Tsyrenov

2023

jour

View full text Add to dashboard Cite

Patients with malignant neoplasms have an increased risk of atrial fibrillation. Prevalence of this pathology among oncological patients is 20–30 %, and it significantly varies depending on tumor type, chemotherapy treatment and initial comorbid status. Atrial fibrillation and malignant neoplasms have similar risk factors. Researchers have identified several possible causes characteristic of these diseases, primarily, systemic inflammation. Some chemotherapies cause abnormalities in ionic channels of atrial cardiomyocytes which leads to changes in the action potential and refractory period, which promote maintenance of atrial fibrillation. The most known groups of chemotherapy drugs associated with atrial fibrillation are alkylating agents (cisplatin, cyclophosphamide), anthracyclines used in sarcoma treatment, as well as anti-HER2 drugs (HER2 – human epidermal growth factor receptor 2), antimetabolites (capecitabine, 5-fluorouracil) and tyrosine kinase inhibitors. However, pathophysiological mechanisms linking together atrial fibrillation and malignant neoplasms require further study.

show abstract

Atrial Fibrillation Induced by Anticancer Drugs and Underling Mechanisms

Cited by 7 publications

References 68 publications

Mid- and long-term risk of atrial fibrillation among breast cancer surgery survivors

Mid- and long-term risk of atrial fibrillation among breast cancer surgery survivors

Advances in basic and translational research in atrial fibrillation

Atrial fibrillation and malignant neoplasms: state of the problem

Contact Info

Product

Resources

About